

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

INSIDE INFORMATION ANNOUNCEMENT PROPOSED ADDITIONAL ISSUE OF H SHARES UNDER GENERAL MANDATE

This announcement is made by Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) pursuant to Rule 17.10(2) of the Rules Governing the Listing of Securities on the Growth Enterprise Market (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, the Board passed a resolution on 17 July 2017 and proposed to issue additional H Shares of not more than 199,500,000 Shares (the “**Proposed Additional Issue of H Shares**”) in accordance with the special resolution, “To grant to the Board a general mandate to issue, allot and deal with additional Domestic Shares/H Shares not to exceed 20% of Domestic Shares in issue and 20% of H Shares in issue of the Company, and to authorise the Board to make such amendments to the articles of association of the Company as it thinks fit so as to reflect the new share capital structure subsequent to allotment and issue of additional Shares”, passed at the annual general meeting on 16 May 2017.

The Company has recently submitted the application materials concerning the Proposed Additional Issue of H Shares to the China Securities Regulatory Commission (the “**CSRC**”) and received on 7 August 2017 the “Acceptance Notice of the Application for Administrative Permission from the CSRC” (No. 171557) (《中國證監會行政許可申請受理通知書》(171557號)) issued by the CSRC indicating that the CSRC will commence review on the application of the Company for the permission of the issue of new H Shares.

As the Proposed Additional Issue of H Shares is subject to approval by the CSRC and the Stock Exchange and the method of additional issue is yet to be determined, the Proposed Additional Issue of H Shares may or may not proceed. Shareholders and potential investors should exercise caution when dealing in securities of the Company.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the People's Republic of China
7 August 2017

As at the date of this announcement, the executive directors of the Company are Sun Li, Hao Zhihui and Liu Renmu; the non-executive directors of the Company are Feng Enqing, Chen Yingzhong and Li Ximing; the independent non-executive directors of the Company are Li Xudong, Duan Zhongpeng and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

The announcement will remain at the "Latest Company Announcements" page on the website of the Growth Enterprise Market at www.hkgem.com for seven (7) days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.